Cambrex to expand generic API R&D capabilities at Milan, Italy site

12 Jun 2018

Company to increase the number of generic APIs in the company's development pipeline.

Cambrex will expand R&D capabilities at its site in Paullo, Milan, Italy. The investment will fund the construction of a new 150-m² R&D laboratory and the recruitment of additional scientists to increase the number of generic APIs in the company’s development portfolio.

Cambrex to expand generic API R&D capabilities at Milan, Italy site

The new laboratory will include 14 fume hoods and will combine both chemistry and analytical development capabilities, with the installation of glass-lined reactors, as well as analytical instruments including multiple high and ultra-performance liquid chromatography, and gas chromatography systems. The building work is estimated to be completed by the end of 2018, allowing installation and validation of the analytical instruments to take place in Q1 2019.

“The generic API industry is growing due to the continued expiry of product patents, which results in the constant flow of new generic entrants to the market,” commented Aldo Magnini, Managing Director, Cambrex Milan. “The new laboratory will increase the number of programs we can be active in at any one time, allowing us to expand our portfolio of generic products.”

Cambrex currently manufactures over 70 generic APIs, which are produced to cGMP standards and the Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant, and development and analytical laboratories.

Read More

Related news

Zenith Technologies sees 400% China growth in latest Asia success

Zenith Technologies sees 400% China growth in latest Asia success

22 May 2019

Company plans to double its operations in the country over the next 3 years and expand its work with local companies as well as continuing to support global multinationals.

Read more 
Online training for pharmaceutical and nutraceutical professionals

Online training for pharmaceutical and nutraceutical professionals

21 May 2019

Modules include a variety of subjects from an ’Introduction to tablet tooling’ and ‘Tooling maintenance’, to ‘Troubleshooting production problems’ and ‘Improving productivity’.

Read more 
FDA approves TraceLink DSCSA pilot submission for network solutions

FDA approves TraceLink DSCSA pilot submission for network solutions

20 May 2019

Delivering 2023 traceability by leveraging blockchain and digital recalls across a supply network.

Read more 
UK and US customers set to benefit from Wasdell Group acquisition

UK and US customers set to benefit from Wasdell Group acquisition

17 May 2019

Increased manufacturing and packaging capacity and service in the UK allows company to better service growing client base in the US who require a fully outsourced supply chain for their products within Europe.

Read more 
Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Legacy plans for lyophilisation boom

Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more